CRP and COVID-19: Interestingly, ACEi/ARB-treated COVID-19 positive patients displayed lower concentrations of CRP and procalcitonin (Yang G. et al., 2020), suggesting that the benefit of ACEi and ARB might rely on their anti-inflammatory effects.